WGU D027 – Advanced Pathopharmacological
Foundations | Final Exam Complete Study Guide
2025/2026 – Verified Final Questions, 100% Correct
Answers & Clinical Rationales | Grade A
Overview: This study guide features 150 verified multiple-choice questions for the D027 final
exam, covering advanced pathophysiology and pharmacology across systems. Questions
integrate clinical scenarios. Correct answers in DARK RED. Rationales provide evidence-based
explanations, mechanisms, and nursing implications.
Question 1: Cardiovascular Pathophysiology
A patient with atherosclerosis presents with intermittent claudication. What is the underlying
mechanism?
A. Vasospasm of arteries
B. Plaque rupture and thrombosis
C. Reduced blood flow due to luminal narrowing
D. Venous insufficiency
Correct Answer: C. Reduced blood flow due to luminal narrowing
Rationale: Atherosclerotic plaques narrow arteries, impairing perfusion distal to obstruction,
causing ischemia on exertion (claudication). Clinically, manage with statins, antiplatelets; A is
Prinzmetal, B acute MI, D varicose veins.
Question 2: Pharmacology - Antihypertensives
First-line therapy for a 55-year-old with HTN and DM?
A. Beta-blocker
B. ACE inhibitor
C. Calcium channel blocker
D. Thiazide diuretic
Correct Answer: B. ACE inhibitor
Rationale: ACEIs (e.g., lisinopril) renoprotective in DM via RAAS inhibition, reduce
proteinuria. Guidelines (ADA/JNC); monitor K+, Cr. A for post-MI, C/D alternatives if
intolerant.
Question 3: Heart Failure Management
In HFrEF, what drug class improves survival?
, A. Loop diuretics
B. ARNI (sacubitril/valsartan)
C. Digoxin
D. Nitrates
Correct Answer: B. ARNI (sacubitril/valsartan)
Rationale: ARNI inhibits neprilysin, enhances natriuretic peptides, reduces mortality
(PARADIGM-HF trial). Add beta-blocker, MRA; A symptom relief, C inotropic, D preload.
Question 4: Respiratory Pathophysiology
COPD exacerbation trigger?
A. Viral infection
B. Allergens
C. Exercise
D. Diet
Correct Answer: A. Viral infection
Rationale: Viruses (rhinovirus) cause 50% exacerbations via inflammation, mucus. GOLD
guidelines: antibiotics if bacterial, steroids, bronchodilators.
Question 5: Asthma Pharmacology
Step-up therapy for uncontrolled asthma on low-dose ICS?
A. Add LABA
B. Switch to high-dose ICS
C. Add montelukast
D. Oral steroids
Correct Answer: A. Add LABA
Rationale: GINA guidelines: ICS/LABA (budesonide/formoterol) for step 3, reduces
exacerbations. Monitor adherence, triggers.
Question 6: Neurological Pathophysiology
Alzheimer's hallmark?
A. Lewy bodies
B. Amyloid plaques and neurofibrillary tangles
C. Dopamine loss
D. Demyelination
Correct Answer: B. Amyloid plaques and neurofibrillary tangles
Rationale: Beta-amyloid deposition, tau hyperphosphorylation lead to neuronal death.
Cholinesterase inhibitors symptomatic.
Foundations | Final Exam Complete Study Guide
2025/2026 – Verified Final Questions, 100% Correct
Answers & Clinical Rationales | Grade A
Overview: This study guide features 150 verified multiple-choice questions for the D027 final
exam, covering advanced pathophysiology and pharmacology across systems. Questions
integrate clinical scenarios. Correct answers in DARK RED. Rationales provide evidence-based
explanations, mechanisms, and nursing implications.
Question 1: Cardiovascular Pathophysiology
A patient with atherosclerosis presents with intermittent claudication. What is the underlying
mechanism?
A. Vasospasm of arteries
B. Plaque rupture and thrombosis
C. Reduced blood flow due to luminal narrowing
D. Venous insufficiency
Correct Answer: C. Reduced blood flow due to luminal narrowing
Rationale: Atherosclerotic plaques narrow arteries, impairing perfusion distal to obstruction,
causing ischemia on exertion (claudication). Clinically, manage with statins, antiplatelets; A is
Prinzmetal, B acute MI, D varicose veins.
Question 2: Pharmacology - Antihypertensives
First-line therapy for a 55-year-old with HTN and DM?
A. Beta-blocker
B. ACE inhibitor
C. Calcium channel blocker
D. Thiazide diuretic
Correct Answer: B. ACE inhibitor
Rationale: ACEIs (e.g., lisinopril) renoprotective in DM via RAAS inhibition, reduce
proteinuria. Guidelines (ADA/JNC); monitor K+, Cr. A for post-MI, C/D alternatives if
intolerant.
Question 3: Heart Failure Management
In HFrEF, what drug class improves survival?
, A. Loop diuretics
B. ARNI (sacubitril/valsartan)
C. Digoxin
D. Nitrates
Correct Answer: B. ARNI (sacubitril/valsartan)
Rationale: ARNI inhibits neprilysin, enhances natriuretic peptides, reduces mortality
(PARADIGM-HF trial). Add beta-blocker, MRA; A symptom relief, C inotropic, D preload.
Question 4: Respiratory Pathophysiology
COPD exacerbation trigger?
A. Viral infection
B. Allergens
C. Exercise
D. Diet
Correct Answer: A. Viral infection
Rationale: Viruses (rhinovirus) cause 50% exacerbations via inflammation, mucus. GOLD
guidelines: antibiotics if bacterial, steroids, bronchodilators.
Question 5: Asthma Pharmacology
Step-up therapy for uncontrolled asthma on low-dose ICS?
A. Add LABA
B. Switch to high-dose ICS
C. Add montelukast
D. Oral steroids
Correct Answer: A. Add LABA
Rationale: GINA guidelines: ICS/LABA (budesonide/formoterol) for step 3, reduces
exacerbations. Monitor adherence, triggers.
Question 6: Neurological Pathophysiology
Alzheimer's hallmark?
A. Lewy bodies
B. Amyloid plaques and neurofibrillary tangles
C. Dopamine loss
D. Demyelination
Correct Answer: B. Amyloid plaques and neurofibrillary tangles
Rationale: Beta-amyloid deposition, tau hyperphosphorylation lead to neuronal death.
Cholinesterase inhibitors symptomatic.
